| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| ln Vitro |
The efficiency of 12-Hydroxystearic acid (12HSA) and its derivatives as gelling agents and their use as lubricants have been the subject of substantial research [1].
|
|---|---|
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
This study assessed the distribution and metabolism of 12-hydroxystearic acid (12-hydroxystearic acid) in 90 young male albino rats (Wistar strain, Slonaker substrain; weighing 43–83 g). The rats were divided into six groups and fed three different diets for 16 weeks: 20% corn oil (control group); 1% hydrogenated castor oil and 19% corn oil; and 10% hydrogenated castor oil and 10% corn oil. Each diet contained 80% laboratory-standard feed. The fatty acid composition of the hydrogenated castor oil added to the diet was: 86.5% 12-hydroxystearic acid, 10.3% non-oxidized fatty acids, and 3.2% 12-ketostearic acid. Therefore, the actual dietary concentrations of 12-hydroxystearic acid ingested by the experimental animals were 0.87% (1% hydrogenated castor oil diet) and 8.7% (10% hydrogenated castor oil diet). Eight weeks after the start of feeding, half of the experimental groups were fed a corn oil diet for the remaining 16 weeks of the study. Lipids were extracted from adipose tissue samples and carcasses (n=3 rats per group) at weeks 8, 12, and 16. The number of surviving rats in each experimental diet at weeks 4, 8, 12, and 16 were 33, 30, 12, and 6, respectively. The number of surviving rats in the control group at weeks 4, 8, 12, and 16 were 15, 15, 12, and 6, respectively. 12-hydroxystearic acid and its metabolites (hydroxypalmitic acid, hydroxymyristic acid, and hydroxylauric acid) were deposited in abdominal fat and other body fat. The percentage composition of hydrogenated castor oil-derived hydroxy fatty acids in rat lipids was: 81% 12-hydroxystearic acid, 17% 10-hydroxypalmitic acid, 1.6% 8-hydroxymyristic acid, and 0.4% 6-hydroxylauric acid. After 4 weeks of feeding a diet containing 8.7% 12-hydroxystearic acid, the highest hydroxy fatty acid content (4.4%) was observed in the abdominal fat of rats. This concentration gradually decreased over the following weeks, falling below 2% at week 16 (roughly the same concentration detected in carcass lipids). Between weeks 8 and 16, the hydroxy fatty acid content (as a percentage of dry carcass body weight) increased in rats fed both diets (containing 0.87% and 8.7% 12-hydroxystearic acid, respectively). At week 8, switching half of the rats' diets to corn oil (control diet) resulted in a rapid decrease in tissue hydroxy fatty acid content. When 2.2 g/day of 12-hydroxystearic acid was added to the diet of a dog (weight not mentioned), 12-hydroxystearic acid accounted for 46% of total fecal fatty acids. When the amount added to the diet was increased to 8.8 g/day, 12-hydroxystearic acid accounted for 60.2% of total fecal fatty acids. No steatorrhea occurred in normal dogs after being fed 12-hydroxystearic acid, and the absorption rate was similar to that of unsubstituted stearic acid. Metabolism/Metabolites 10-hydroxypalmitic acid and 8-hydroxymyristic acid were identified as metabolites of 12-hydroxystearic acid. |
| Toxicity/Toxicokinetics |
Interactions
Low molecular weight gelling agents can form soft solids in various organic liquids and vegetable oils. These soft solids are commonly referred to as organic gels. This study investigated organic gels prepared using 12-hydroxystearic acid (12-HSA) as a gelling agent and soybean oil as a matrix, and studied their properties as controlled-release formulations of lipophilic compounds. The release rate of the model lipophilic compound ibuprofen from the organic gel decreased with increasing 12-HSA concentration in the formulation; however, differences in 12-HSA concentration in the formulation did not affect the diffusion coefficient of ibuprofen in the organic gel. This study used simulated gastric and intestinal fluids to investigate the erosion constant of the organic gel in the intestine. The results showed that the organic gel was very stable in simulated gastric fluid regardless of the 12-HSA concentration in the formulation. On the other hand, in simulated intestinal fluid, the erosion constant of the organic gel increased with decreasing 12-HSA concentration. Therefore, it is speculated that the difference in ibuprofen release rate among organic gels at different 12-HSA concentrations is mainly caused by differences in erosion rate. To characterize the in vivo effects of the organic gel, ibuprofen was orally administered to rats in either an aqueous suspension or the organic gel form. The results showed that after oral administration of the aqueous suspension, plasma ibuprofen concentration increased rapidly, while the organic gel inhibited its rapid absorption. In conclusion, the organic gel shows promising application potential as an oral controlled-release formulation of lipophilic compounds. |
| References | |
| Additional Infomation |
12-Hydroxyoctadecanoic acid is a hydroxy fatty acid, a compound of stearic acid with a hydroxyl substituent at the 12-position. It is both a plant metabolite and a bacterial xenobiotic metabolite. It is a hydroxyoctadecanoic acid and a secondary alcohol. It is the conjugate acid of 12-hydroxyoctadecanoate.
12-Hydroxyoctadecanoic acid has been reported in Bacillus cereus and Elaeagnus angustifolia, with relevant data available. See also: Pentaerythritol tripolyhydroxystearate (monomer); Polyglycerol-2-dipolyhydroxystearate (monomer). Polyhydroxystearic acid (2300 MW) (monomer)...see more... Mechanism of Action In a study on primary and secondary lipid peroxidation products as regulators of DNA synthesis, we treated mouse Lewis cancer cells with physiological concentrations (50 and 100 μM) of hydroxystearic acid. The test substance was dissolved in 90% ethanol and then added to the culture medium. DNA profiling obtained by flow cytometry analysis of the cell cycle revealed that cell accumulation in the G2-M phase was time- and dose-dependent compared to untreated exponential growth phase cells. To determine whether this effect was mediated by the interaction of hydroxystearic acid with the cyclin-dependent kinase-cyclin complex, we measured histone H1 kinase activity in crude C108 cell extracts. We found that hydroxystearic acid inhibited histone H1 kinase activity by up to 95% in mitotic cells (synchronous control C108 cells). 12-Hydroxystearic acid (30 μM) also induced mitochondrial ATPase activity. Lutamycin (which blocks ATP phosphorylation) inhibited ATPase activity; this inhibition is expected for ATP-powered mitochondrial responses. 30 pM 12-hydroxystearic acid induced a small but significant change in mitochondrial volume (swelling) without ATP assistance. Respiratory inhibitors antimycin or dinitrophenol inhibited this swelling, while rutamycin did not; therefore, this swelling is dependent on oxidative phosphorylation. Adding ATP to the reaction mixture enhanced 12-hydroxystearic acid-induced mitochondrial swelling. Researchers concluded that 12-hydroxystearic acid interferes with the oxidative phosphorylation mechanism in rat liver mitochondria. Therapeutic Uses /Experimental Therapy/ Low molecular weight gelling agents can form soft solids in a variety of organic liquids and vegetable oils. These soft solids are commonly referred to as organic gels. …This study investigated organic gels prepared using 12-hydroxystearic acid (12-HSA) as a gelling agent and soybean oil as a solvent, and studied their properties as controlled-release formulations of lipophilic compounds. …Organic gels can clearly be used as oral controlled-release formulations of lipophilic compounds. |
| Molecular Formula |
C18H36O3
|
|---|---|
| Molecular Weight |
300.47664
|
| Exact Mass |
300.266
|
| CAS # |
106-14-9
|
| Related CAS # |
12-Hydroxystearic acid-d5;2468637-39-8
|
| PubChem CID |
7789
|
| Appearance |
White to off-white solid powder
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
436.3±18.0 °C at 760 mmHg
|
| Melting Point |
80-81ºC
|
| Flash Point |
231.8±17.7 °C
|
| Vapour Pressure |
0.0±2.4 mmHg at 25°C
|
| Index of Refraction |
1.468
|
| LogP |
6.03
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
21
|
| Complexity |
229
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
ULQISTXYYBZJSJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H36O3/c1-2-3-4-11-14-17(19)15-12-9-7-5-6-8-10-13-16-18(20)21/h17,19H,2-16H2,1H3,(H,20,21)
|
| Chemical Name |
12-hydroxyoctadecanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~332.80 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.32 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3280 mL | 16.6400 mL | 33.2801 mL | |
| 5 mM | 0.6656 mL | 3.3280 mL | 6.6560 mL | |
| 10 mM | 0.3328 mL | 1.6640 mL | 3.3280 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.